Cargando…

An overview of preclinical animal models for SARS-CoV-2 pathogenicity

Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of fatalities globally since its origin in November 2019. The SARS-CoV-2 shares 79 and 50 per cent genome similarity with its predecessors, severe SARS-CoV and Middle East respiratory syndrome (MERS) coronavirus, all belo...

Descripción completa

Detalles Bibliográficos
Autores principales: Munshi, Itti, Khandvilkar, Aditya, Chavan, Shrinivas M., Sachdeva, Geetanjali, Mahale, Smita D., Chaudhari, Uddhav K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184076/
https://www.ncbi.nlm.nih.gov/pubmed/33818465
http://dx.doi.org/10.4103/ijmr.IJMR_3215_20
_version_ 1783704515639246848
author Munshi, Itti
Khandvilkar, Aditya
Chavan, Shrinivas M.
Sachdeva, Geetanjali
Mahale, Smita D.
Chaudhari, Uddhav K.
author_facet Munshi, Itti
Khandvilkar, Aditya
Chavan, Shrinivas M.
Sachdeva, Geetanjali
Mahale, Smita D.
Chaudhari, Uddhav K.
author_sort Munshi, Itti
collection PubMed
description Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of fatalities globally since its origin in November 2019. The SARS-CoV-2 shares 79 and 50 per cent genome similarity with its predecessors, severe SARS-CoV and Middle East respiratory syndrome (MERS) coronavirus, all belonging to the same genus, Betacoronavirus. This relatively new virus has stymied the effective control of COVID-19 pandemic and caused huge social and economic impact worldwide. The FDA-approved drugs were re-purposed to reduce the number of fatalities caused by SARS-CoV-2. However, controversy surrounds about the efficacy of these re-purposed antiviral drugs against SARS-CoV-2. This necessitates the identification of new drug targets for SARS-CoV-2. Hence, the development of pre-clinical animal model is warranted. Such animal models may help us gain better understanding of the pathophysiology of SARS-CoV-2 infection and will be effective tools for the evaluation and licensure of therapeutic strategies against SARS-CoV-2. This review provides a summary of the attempts made till to develop a suitable animal model to understand pathophysiology and effectiveness of therapeutic agents against SARS-CoV-2.
format Online
Article
Text
id pubmed-8184076
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Wolters Kluwer - Medknow
record_format MEDLINE/PubMed
spelling pubmed-81840762021-06-21 An overview of preclinical animal models for SARS-CoV-2 pathogenicity Munshi, Itti Khandvilkar, Aditya Chavan, Shrinivas M. Sachdeva, Geetanjali Mahale, Smita D. Chaudhari, Uddhav K. Indian J Med Res Review Article Severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has caused millions of fatalities globally since its origin in November 2019. The SARS-CoV-2 shares 79 and 50 per cent genome similarity with its predecessors, severe SARS-CoV and Middle East respiratory syndrome (MERS) coronavirus, all belonging to the same genus, Betacoronavirus. This relatively new virus has stymied the effective control of COVID-19 pandemic and caused huge social and economic impact worldwide. The FDA-approved drugs were re-purposed to reduce the number of fatalities caused by SARS-CoV-2. However, controversy surrounds about the efficacy of these re-purposed antiviral drugs against SARS-CoV-2. This necessitates the identification of new drug targets for SARS-CoV-2. Hence, the development of pre-clinical animal model is warranted. Such animal models may help us gain better understanding of the pathophysiology of SARS-CoV-2 infection and will be effective tools for the evaluation and licensure of therapeutic strategies against SARS-CoV-2. This review provides a summary of the attempts made till to develop a suitable animal model to understand pathophysiology and effectiveness of therapeutic agents against SARS-CoV-2. Wolters Kluwer - Medknow 2021 /pmc/articles/PMC8184076/ /pubmed/33818465 http://dx.doi.org/10.4103/ijmr.IJMR_3215_20 Text en Copyright: © 2021 Indian Journal of Medical Research https://creativecommons.org/licenses/by-nc-sa/4.0/This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.
spellingShingle Review Article
Munshi, Itti
Khandvilkar, Aditya
Chavan, Shrinivas M.
Sachdeva, Geetanjali
Mahale, Smita D.
Chaudhari, Uddhav K.
An overview of preclinical animal models for SARS-CoV-2 pathogenicity
title An overview of preclinical animal models for SARS-CoV-2 pathogenicity
title_full An overview of preclinical animal models for SARS-CoV-2 pathogenicity
title_fullStr An overview of preclinical animal models for SARS-CoV-2 pathogenicity
title_full_unstemmed An overview of preclinical animal models for SARS-CoV-2 pathogenicity
title_short An overview of preclinical animal models for SARS-CoV-2 pathogenicity
title_sort overview of preclinical animal models for sars-cov-2 pathogenicity
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8184076/
https://www.ncbi.nlm.nih.gov/pubmed/33818465
http://dx.doi.org/10.4103/ijmr.IJMR_3215_20
work_keys_str_mv AT munshiitti anoverviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT khandvilkaraditya anoverviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT chavanshrinivasm anoverviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT sachdevageetanjali anoverviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT mahalesmitad anoverviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT chaudhariuddhavk anoverviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT munshiitti overviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT khandvilkaraditya overviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT chavanshrinivasm overviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT sachdevageetanjali overviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT mahalesmitad overviewofpreclinicalanimalmodelsforsarscov2pathogenicity
AT chaudhariuddhavk overviewofpreclinicalanimalmodelsforsarscov2pathogenicity